PubMed Health⌕ Search

Biomedical subjects

H Erzigkeit

Publications and source records attributed to H Erzigkeit.

25 records · Page 2Linked to original sources
PubMed1977

[Psychopathometrical results of follow-up studies of trichloroethylene-exposed persons (author's transl)].

Seven clinical healthy volunteers were exposed to trichloroethylene concentration in air with 520 mg/m3 (100 ppm) at an average 6 hours a day on 5 consecutive days. Corresponding volunteers were exposed to a placebo for the same period. --The persons were examined psychopathometrically and biochemically at the beginning and after every day of exposure. The trichloroethylene-metabolites in blood and urine were dated in order to quantify the loads. --Purpose of the psychopathometrical testing methods was the observation, whether a psychological impairment in the sense of a "psychoorganic syndrome" may occur under these exposition-conditions. --Standardized achievement-tests and self-report rating scales were used in order to demonstrate reversible physical provable psychosis that may be possible. Comparing the psychopathometrical results of the exposed and non-exposed volunteers no statistical significant difference was visible in spite of the analytically proved considerable incorporation of the solvent.

Adult↗
PubMed1977

[Psychopathometric methods for the testing of psychopharmaceuticals. Efficiency increase].

The rentability of tests of psychopharmacological drugs can essentially be influenced by psychopathometric procedures. Shortness and simplicity of the test decisively adds to the rentability and the validity of the examination. Procedures considering patients' demands, also demand a high amount of variation and robustness by which (1) the validity is increased and (2) the rentability is decreased. Investigations in time series make further economizing of tests possible, if - valid for reversible physically caused psychosis and cyclothymical depression - symptoms and syndromes will be changed in a rectifying manner. This is shown in a study with the antidepressant Mefexamid given to depressive patients. From these patients were taken one objective and three self-rating scales. In these cases each test on its own gave 84% of the information which it had given together with a second scale.

Antidepressive Agents↗
PubMed1975

[The multiple selection vocabulary test (MSVT-B)--an accelerated intelligence test].

A new accelerated intelligence test is presented which is known as the multiple selection vocabulary test B. This is a very objective and reliable test measuring the general level of intelligence. The time of testing will be about three to five minutes in the case of persons that are free of any psychiatric disorders. Test results will be only negligibly influenced by psychic and mental disorders.

Humans↗
PubMedDate not supplied

The Bayer-Activities of Daily Living Scale (B-ADL): results from a validation study in three European countries.

The Bayer-Activities of Daily Living Scale (B-ADL) is a 25-item, informant-rated questionnaire which was developed as a brief and internationally applicable instrument for assessing functional disabilities. The scale's target group are elderly patients suffering from mild to moderate dementia or cognitive impairment. To investigate the reliability and validity of different language versions, the B-ADL was administered in the UK, Germany, and Spain to a total of 1,433 subjects with a wide range of cognitive decline. The results from the three country samples were very similar, with internal consistency being above 0.98 (Cronbach alpha). A factor analysis revealed that a one-factor solution accounted for most of the variance. The B-ADL total score significantly increased between adjacent Global Deterioration Scale (GDS) stages 1 to 5. A second factor analysis entering additional variables (GDS stage, Mini-Mental State Examination or MMSE subscores, age, years of education, gender, and country) revealed that all B-ADL items loaded on the same factor, "dementia severity", and that they were not related to age, education, gender, or country. In the identification of subjects with clinically manifest dementia symptoms (GDS stages 4 and 5), the B-ADL proved to be as efficient as the MMSE in the UK and German samples and superior to the MMSE in the Spanish sample.

Activities of Daily Living↗
PubMedDate not supplied

Outcome measures for the study of activities of daily living in vascular dementia.

Decline in functional abilities is a major component of the dementia syndrome. The definition of dementia in the International Classification of Diseases (10th rev.) requires a cognitive impairment sufficient to impair personal activities of daily living (ADL). The Diagnostic and Statistical Manual of Mental Disorders (4th ed.) also requires cognitive deficits sufficiently severe to cause impairment in occupational or social functioning and must represent a decline from a higher level of functioning. However, the term disability is more appropriate than impairment to describe a loss in activities, as opposed to a loss of elementary functions, and is consistent with World Health Organization definitions of impairment, disability, and handicap. There is no doubt that ADL outcomes are required in therapeutic drug studies on vascular dementia, and there is a good rationale and some evidence for the use of ADL scales developed for therapeutic research in Alzheimer disease, favoring scales devoid of items sensitive to physical disabilities. Similarly, ADL-related clinical milestones could be used for longer-term studies aiming predominantly at slowing progression of disease in both early and later stages of dementia. Slower decline in ADL and delay in reaching ADL-related clinical milestones should be considered as valid outcomes by regulatory bodies in the process of dementia drug approval.

Activities of Daily Living↗